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Overexpression of the epidermal growth factor receptor (EGFR) is observed in a large number of neoplasms. The
monoclonal antibody cetuximab/Erbitux is frequently applied to treat EGFR-expressing tumors. However, the
application of cetuximab alone or in combination with radio- and/or chemotherapy often yields only little benefit for
patients. In the present study, we describe a mechanism that explains resistance of both tumor cell lines and
cultured primary human glioma cells to cetuximab. Treatment of these cells with cetuximab promoted DNA
synthesis in the absence of increased proliferation, suggesting that DNA repair pathways were activated. Indeed,
we observed that cetuximab promoted the activation of the DNA damage response pathway and prevented the
degradation of essential meiotic endonuclease 1 homolog 1 (Eme1), a heterodimeric endonuclease involved inromo-2'-deoxyuridine); Chk, checkpoint kinase; DDR, DNA damage response; EGFR,
, extracellular signal-regulated kinase; GBM, glioblastoma multiforme; Mus81, methyl
ranscription 3
logy and Department of Neurosurgery, Medical Faculty, RWTH Aachen University,
achen.de
nd their function,” Medical Faculty, RWTH Aachen University (Aachen, Germany).
ublished before, and is not currently being considered for publication elsewhere. We
nd that there has been no significant financial support for this work that could have
y all named authors and that there are no other persons who satisfied the criteria for
e protection of intellectual property associated with this work and that there are no
ctual property. In so doing, we confirm that we have followed the regulations of our
7 and are available online at www.neoplasia.com.
208 DNA Repair in Cetuximab Resistance Weinandy et al. Neoplasia Vol. 16, No. 3, 2014DNA repair. The increased levels of Eme1 were necessary for enhanced DNA repair, and the knockdown of Eme1
was sufficient to prevent efficient DNA repair in response to ultraviolet-C light or megavoltage irradiation. These
treatments reduced the survival of tumor cells, an effect that was reversed by cetuximab application. Again, this
protection was dependent on Eme1. Taken together, these results suggest that cetuximab initiates pathways that
result in the stabilization of Eme1, thereby resulting in enhanced DNA repair. Accordingly, cetuximab enhances
DNA repair, reducing the effectiveness of DNA-damaging therapies. This aspect should be considered when using
cetuximab as an antitumor agent and suggests that Eme1 is a negative predictive marker.
Neoplasia (2014) 16, 207–220.e4Introduction
Overexpression of the epidermal growth factor receptor (EGFR) is
found in many tumors and has been linked to increased cell
proliferation, angiogenesis, and decreased apoptosis [1]. Diverse
strategies have been established to target and inhibit the EGFR in
tumors, including monoclonal antibodies and tyrosine kinase
inhibitors [2]. Cetuximab (Erbitux; Merck KgAa, Darmstadt,
Germany; IMC-C225) is a recombinant, chimeric human-murine
IgG1 antibody, which was developed to inhibit growth of tumor cells
by binding to the extracellular domain of the EGFR, thus preventing
ligand binding and subsequent activation of downstream signal
transduction pathways [3]. However, the use of this monoclonal
antibody alone provides response rates of only about 11% in
advanced, pretreated, and recurrent malignancies [4]. The therapeutic
efficacy is higher if cetuximab is combined with chemotherapy or
radiotherapy, leading to a response rate of up to 23 %, which is still
quite low [4,5]. Increasing evidence indicates that many patients
develop resistance to cetuximab therapy [6]. Mutations in KRAS,
EGFR, and BRAF or the activation of other receptor tyrosine kinases
such as erythroblastosis oncogene B2 (erbB2) or ErbB3 limit the
beneficial effects of cetuximab by bypassing EGFR signaling [6-8].
Moreover, tumor progression is frequently associated with
alterations in DNA repair pathways [9]. This dysfunctional DNA
repair capacity results in genomic instability of tumor cells [10].
Recent reports have demonstrated that defective DNA repair in tumor
cells can be linked to acquired therapy resistance [11]. Therefore,
novel agents that target DNA repair pathways in tumors are under
investigation [12]. Interestingly, a recent study showed that treatment
with cetuximab and the poly-ADP-ribose polymerase inhibitor ABT-
888 enhances cell death in comparison to cetuximab alone [13].
In the present study, we addressed the mechanism of acquired
cetuximab resistance in several tumor entities. We found that
cetuximab led to increased protein levels of the DNA repair–related
endonuclease essential meiotic endonuclease 1 homolog 1 (Eme1)
in tumor cell lines as well as in primary cultures of human
glioblastoma cells [14]. Eme1 is a regulatory subunit of the
heterodimeric endonuclease methyl methanesulfonate–sensitive
UV-sensitive 81 (Mus81)/Eme1, which belongs to the xeroderma
pigmentosum group F (XPF)/Mus81 protein family and acts by
cleaving stalled or blocked replication forks, thereby promoting
DNA repair and maintaining genomic integrity [14,15]. The
elevated Eme1 protein levels resulted in increased DNA repair in
the tumor cells. Moreover, cetuximab treatment protected these
cells from apoptosis triggered by exposure to ultraviolet-C (UVC)light or by megavoltage irradiation–induced DNA damage. This
protective effect was dependent on elevated levels of Eme1.
Taken together, these findings strongly suggest that Eme1 is a
negative predictive marker for a combination therapy of cetuximab
with treatment that induces DNA damage such as radiotherapy.
Materials and Methods
Cell Culture and Drug Treatments
A431 and A172 were obtained from the American Type Culture
Collection (ATCC) (Manassas, VA); MDA-MB-231 cells were
obtained from Prof Dr E. Dahl (Institute of Pathology, RWTH
Aachen University, Aachen, Germany). All cell lines were cultured in
Dulbecco′s modified Eagle’s medium (Gibco, Carlsbad, CA) with
10% FBS (BioWest, Nuaillé, France).
For EGFR inhibition, concentrations of 50, 100, and 500 μg/ml of
themonoclonal antibody cetuximab (Erbitux) were used; concentrations
of up to 100 μg/ml have been used previously in experimental studies on
cetuximab effects [6,16].
Glioblastoma Samples
From October to December 2012, glioblastoma samples from 10
consecutive patients with a histologically proven supratentorial
glioblastoma multiforme (GBM) (World Health Organization
(WHO) grade IV) were included. Samples were provided by the
local Department of Neurosurgery (RWTH Aachen University).
Experiments were approved by the local ethics committee of the
Medical Faculty, RWTH Aachen University (EK 220/12). Subjects
gave written informed consent for their participation.
Culture of Primary Glioblastoma Cells
Samples were processed within 2 hours after surgical removal.
Tumor cells were washed and dissociated by mechanical and
enzymatic means into single cells, resuspended in Dulbecco′s
modified Eagle’s medium/20% FBS, and cultured on poly-L-Lysine
(PLL) (Sigma-Aldrich, St Louis, MO)–coated plates. Medium was
changed the next day to remove erythrocytes. Experiments were
performed with cells from passage No. 2.
Radiotherapy
Cells were irradiated with megavoltage X rays (linear accelerator;
Siemens, Erlangen, Germany) or UVC (germicidal lamp, 200-280 nm;
intensity = 135 J/cm2 or 270 J/cm2; OSRAM, München, Germany)
24 hours after addition of cetuximab. Radiotherapy was performed as a
Neoplasia Vol. 16, No. 3, 2014 DNA Repair in Cetuximab Resistance Weinandy et al. 2096-MV single-shoot irradiation of 10 or 20 Gray (Gy) at the local
Department of Radiation Oncology (RWTH Aachen University).
Cell Number Assay (Cell Counting)
Cells were seeded onto culture dishes containing a grid (2 × 2 mm)
and incubated without or with cetuximab for 72 hours. Cell numbers
were determined by counting, and control (without cetuximab) was
set as 100%.
Apoptosis/Necrosis Assay (FACS)
Cells were detached from cell culture dish with Accutase
(Invitrogen, Grand Island, NY). For detection of necrotic and
apoptotic cells, Propidium Iodide (Sigma-Aldrich) and annexin V,
Pacific Blue (Invitrogen) were added to Annexin buffer (10 mM
Hepes, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4). Cells were analyzed
by flow cytometry using a FACSCanto II (BD Biosciences, Franklin
Lakes, NJ, USA). Data were analyzed using FlowJo (Tree Star Inc.,
Ashland, OR, USA) software.
DNA Synthesis Assay (Bromodeoxyuridine)
Cells were seeded onto PLL-coated glass coverslips and incubated
for the indicated periods of time. Bromodeoxyuridine (5-bromo-2'-
deoxyuridine) (BrdU; 10μM, Sigma-Aldrich) was added to culture
medium for 20 minutes before rinsing with phosphate-buffered saline
and fixation with 4% paraformaldehyde (15 minutes). DNA was
denatured with 2 NHCl for 15 minutes at 37°C. Cells were incubated
with 0.1 M sodium borate (Sigma-Aldrich) (pH 8.5) for 10 minutes.
Indirect immunofluorescence (IF) was carried out as described
previously [17]. Cells were incubated with the primary antibody
against BrdU (1:100) overnight and with Hoechst 33342 (1:10 000;
Invitrogen) and secondary antibody (1:1000) for 1 hour. Images were
analyzed using AxioVision Rel.4.6 (Carl Zeiss, Oberkochen,
Germany) to determine the percentage of the BrdU-labeled cells.
Cell Viability (alamarBlue)
Cells were seeded onto PLL-coated 24-well tissue culture dishes
and 24 hours later transfected with small interfering (si)RNA and/
or incubated in the absence or presence of cetuximab for the
indicated periods of time. alamarBlue (Invitrogen) assay was
performed following the manufacturer’s instructions. To determine
cellular metabolic activity, the fluorescence was monitored
(wavelengths = 530 nm, excitation; 590 nm, emission) with a
microplate reader (FLUOstar OPTIMA; BMG Labtech, Ortenberg,
Germany). For analysis, viability mean value of cells grown in the
absence of cetuximab (control) was set as 100%.
RNA Isolation and cDNA Synthesis
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,
Valencia, CA) according to themanufacturer’s recommendations. Cell
lysates were homogenized using QIAshredder (Qiagen) columns, and
genomic DNA was digested by the RNAse-free DNase set (Qiagen)
for 15 minutes at room temperature (RT). The concentration of RNA
was determined using a Photometer (Eppendorf, Hamburg, Germany).
cDNA was synthesized with the Reverse Transcription System
(Promega, Fitchburg, WI). For cDNA synthesis, one microgram of
RNA was applied.
Transient Transfection
Transient transfections with d1EGFP (Clontech, Mountain
View, CA, USA), which encodes an unstable EGFP that can beused as a reporter to measure ubiquitin-proteasome–dependent
degradation, were performed using Lipofectamine 2000 reagent
(Invitrogen) according to the manufacturer’s recommendations.
siRNA, siRNA Transfection, and Quantitative Real-Time
Polymerase Chain Reaction
Cells were transfected using HiPerFect (Qiagen) following
manufacturer’s instructions. The efficiency of each transfection
was monitored by quantitative real-time polymerase chain reaction
(PCR) and Western blot (WB) analysis 48 hours after transfection.
siRNA (siGENOME SMART pool) against human Eme1 (siEme1)
and control nontargeting siRNA (siGENOME) (siC) were
purchased from Dharmacon (Thermo Fisher Scientific, Lafayette,
CO, USA). One microgram of cDNA was used for quantitative
real-time PCR using SensiMix Plus SYBR Kit (Bioline, London,
United Kingdom) following manufacturer’s recommendations and
run on a Rotor-Gene 6000 (Corbett Life Science/Qiagen) machine.
Mean mRNA levels of the gene of interest were calculated relative
to the levels of ß-glucoronidase. For mRNA quantification, the
following primer pairs were used: ß-glucoronidase, 5’-
CTCATTTGGAATTTTGCCGATT-3’ and 5’-CCGAGTGAA-
GATCCCCTTTTTA-3’; Eme1 primers were purchased from
Qiagen (QT00079940).
Lysate Preparation and WB Analysis
WB analysis was carried out as described previously [17]. The
membrane was probedwith the following first antibodies used: fromCell
Signaling Technology (Danvers, MA, USA), (dilution 1:1,000) anti-
EGFR, anti-phospho (p)EGFR (Y1173), anti-pAkt (S473), anti-Akt,
anti–phospho-extracellular signal-regulated kinase (anti-pErk) (T202/
204), anti-Erk, anti–phospho-signal transducer and activator of
transcription 3 (anti-pSTAT3) (Y705), anti-STAT3, anti–Bcl extra
large (anti-BclXL), anti–B cell lymphoma 2 (Bcl2), anti–phospho-
checkpoint kinase 1 (anti-pChk1) (S345), anti-pChk2 (T68), anti-
pHistone H2A.X (S139), anti-p-p53 (S15), anti–phospho-breast cancer
tumor suppressor 1 (anti-pBRCA1) (S1524), anti-pWee1 (S642), and
anti-Wee1; from Abcam (Cambridge, England), anti-Eme1 (1:1000);
from Sigma-Aldrich (St. Louis, MO, USA), anti–α-Tubulin (1:10,000);
and from Santa Cruz (Santa Cruz, CA, USA) Biotechnology, anti-
Ubiquitin (1:1000). As secondary antibodies (dilution 1:5,000), goat
anti-mouse and goat anti-rabbit, both HRP conjugated (Thermo
Scientific), were used. Immunoreactive proteins were detected by
enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ).
Densitometric quantification of the band intensity was normalized to
α-Tubulin levels using Adobe Photoshop CS5 (San Jose, CA, USA).
Alkaline Comet Assay
To detect radiation-induced DNA damage, a Comet Assay kit
(Cell Biolabs, Inc, San Diego, CA) was used according to the
manufacturer’s instructions. Alkaline electrophoresis took place at
1 V/cm for 30 minutes at 4°C. The comet images were captured with
Carl Zeiss Axiovert 200 M (Carl Zeiss, Oberkochen, Germany)
inverted fluorescence microscope. The lengths of 30 comet tails were
randomly measured per slide (distance measured from the center of
the head to the end of the tail using AxioVision Rel.4.6).
Immunofluorescence
Indirect IF was carried out as described previously [17]. The
following first antibodies (dilution 1:100) were used: anti-Eme1
Figure 1. Effects of cetuximab on EGFR signaling and cell proliferation. (A) A431 cells were treated with 100 μg/ml cetuximab for the
indicated periods of time. Whole-cell lysates were analyzed for the expression and phosphorylation of the designated proteins by
immunoblot analysis. (B) A431 cells were treated with the indicated amounts of cetuximab for 72 hours. The cells were then counted and
compared to the control (set to 100%). The differences in cell number in response to cetuximab treatment were not statistically
significant. The data represent mean values and SDs of three experiments. (F) A431 cells were treated with cetuximab for 48 hours. DNA
synthesis was measured by incorporation of BrdU. That was added during the last 30 minutes before cells were fixed. The data represent
mean values and SDs of three experiments. (C) A431 cells were incubated with the indicated amounts of cetuximab for 14 days.
Metabolic activity was measured using the alamarBlue assay. The quantification is representative of three independent experiments. (D)
Image was taken 14 days after addition of cetuximab (100 μg/ml) and of untreated A431 cells. (E) A 431 cells were treated for indicated
periods of time. The expression of the indicated proteins was analyzed in whole-cell lysates by immunoblot analysis. #P N .05; *P b .05;
and **P b .01.
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1:1000) were used: Alexa Fluor™ 488–conjugated anti-rabbit,
Alexa Fluor™ 555–conjugated anti-mouse and Alexa Fluor™ 555–
conjugated anti-rabbit (Invitrogen). Hoechst 33342 was obtained
from Sigma-Aldrich. Images were taken with Carl Zeiss Axiovert
200 M inverted fluorescence microscope and equipped with an
ApoTome (Carl Zeiss, Oberkochen, Germany) slider. Images were
analyzed using AxioVision Rel.4.6.Statistical Analysis
Unpaired Student’s t test was used to evaluate significance between
two sample groups. Values were expressed as means ± SD from three
independent experiments. Differences were considered as statistically
significant when P b .05. Error bars indicate the SD of triplicate
measurement, (*) indicates significance in comparison to controls
with (***) = P b .001, (**) = P b .01, and (*) = P b .05; (#) indicates
no significant difference.
Figure 2. Effects of cetuximab on the expression of the Eme1 endonuclease. (A) A431 cells were treated with 100 μg/ml cetuximab.
Lysates were prepared at the indicated time points and subjected to WB analysis using the indicated antibodies. (B) Densitometric
analysis of Eme1 from Figure 2A; the data represent mean values and SDs of three experiments. (C) A431 cells were incubated with 1, 10,
or 100 μg/ml cetuximab for 1 and 72 hours. Cell lysates were analyzed by immunoblot analysis to detect Eme1 and α-Tubulin. (D) A431
cells were pretreated for 4 hours with 5 μM Stattic. Cetuximab was added for 1 hour. Lysates were subjected to WB analysis using the
indicated antibodies.( E) A431 cells were left untreated or were incubated with 100 μg/ml cetuximab for 24 hours. Eme1 (red) was
detected by indirect IF; Hoechst nuclear counterstain (blue); scale bar, 10 μm. (F) Fluorescence intensity of Eme1 was quantified in the
nuclei of 20 cells per experiment. The graphs show mean values and SDs of three experiments; AU, arbitrary units.
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Cetuximab Inhibits Activation of EGFR, Akt, and Erk1/2 but
Stimulates STAT3
Cetuximab prevents binding of ligands to the EGFR and
thereby inhibits the subsequent activation of downstream signal
transduction pathways [3]. A431 cells, which express high levels of
the EGFR, show tyrosine phosphorylation of the receptor and
strong Erk phosphorylation when grown in medium containing
serum. In line with published results [18], we found that
incubation of A431 cells with 100 μg/ml cetuximab reduced
receptor phosphorylation and led to down-regulation and
decreased activity of EGFR (Figure 1A). Moreover, this treatment
resulted in decreased phosphorylation of the downstream signaling
kinases Akt and Erk1/2 (Figure 1A). In contrast, increased STAT3phosphorylation was observed (Figure 1A). Together, these
findings suggested that cetuximab treatment affected distinct
signaling pathways inversely.
Cetuximab Fails to Affect Cell Proliferation but Increases
DNA Synthesis
In several studies, incubation of A431 cells with cetuximab
resulted in a decrease of cell numbers [19,20]. In these studies, cells
were detached from the cell culture plates before the cell survival
assay. In the current study, we confirmed that cetuximab treatment
and subsequent detachment induced cell death (Figure W1A).
However, we also observed that nondetached A431 cells did
not show reduced cell proliferation or viability during incubation
for 72 hours with cetuximab (Figures 1B and W1B). Only when
A431 cells were incubated for 14 days with cetuximab (10 and
Figure 3. Cetuximab treatment induces Eme1protein stability. (A)Quantitative real-timePCR analysis ofEme1 target gene in A431 cells after
treatment with or without cetuximab for 48 hours. Error bars represent SDs of biologic triplicates. (B) A431 cells were treated with 3μM
MG132 for 4 hours; 100 μg/ml cetuximab was added during the last 2 hours. Whole-cell lysates were analyzed for the indicated proteins by
immunoblot analysis. (C) Densitometric quantification of Eme1 from B; the data represent mean values and SDs of three experiments. (D)
A431 were transfected either with green fluorescence protein (GFP) or d1EGFP plasmids; 24 hours after transfection, MG132 (3 μM) or
cetuximab (100 μg/ml) was added for additional 24 hours. Cell lysates were analyzed for the indicated proteins by immunoblot analysis.
212 DNA Repair in Cetuximab Resistance Weinandy et al. Neoplasia Vol. 16, No. 3, 2014100 μg/ml) cell viability and growth were decreased by 10%
(Figure 1, C and D). This was consistent with the constant
expression of antiapoptotic proteins Bcl extra large (BclXL) and B
cell lymphoma 2 (Bcl2) (Figure 1E). Instead, cetuximab was found
to stimulate the incorporation of BrdU, suggesting that the cells
responded with enhanced DNA synthesis (Figure 1F). Together,
these findings indicated that cetuximab induces DNA synthesis in
the absence of enhanced cell proliferation.
STAT3 Signaling Is Crucial for Cell Survival
As shown above, treatment of A431 cells with cetuximab stimulated
the phosphorylation of STAT3, a modification that is associated with
enhanced activity (Figure 1A). Previous reports documented STAT3 as
an important factor responsible for tumor cell survival and proliferation
[21,22]. To address the role of STAT3 signaling for the survival of
A431 cells on cetuximab treatment, we incubated these cells with the
small-molecule STAT3 inhibitor Stattic (Sigma-Aldrich, St. Louis,
MO, USA), which prevents dimerization and nuclear accumulation of
the STAT3 protein [23]. The inhibition of STAT3 reduced cell
viability in a dose-dependent manner within 24 hours (Figure W2),
implying that STAT3 signaling is crucial for A431 cell viability.Cetuximab Causes Up-Regulation of Eme1
DNA synthesis occurs during cell proliferation, when DNA is
replicated [24]. However, on the basis of the results described above,
the increase in DNA synthesis in the presence of cetuximab did not
correlate with enhanced proliferation (Figure 1, B and C). DNA
synthesis also occurs during DNA repair [25]. Moreover, recent
studies described a functional link between STAT3 and Eme1/
Mus81, a heterodimeric endonuclease involved in DNA repair [26].
Therefore, we investigated the influence of cetuximab on the
expression of Eme1, because this protein is the regulatory subunit
of the functional endonuclease complex [27]. We found that
incubation of A431 cells with 100 μg/ml cetuximab for up to 72
hours stimulated the expression of Eme1 (Figure 2A; quantification in
Figure 2B). Moreover, even lower concentrations of cetuximab (1 and
10 μg/ml) led to elevated levels of Eme1 (Figure 2C ).
STAT3 Activation Leads to Elevated Levels of Eme1
To investigate if STAT3 inhibition blocks cetuximab-induced
Eme1 up-regulation, we inhibited STAT3 activity with Stattic.
Indeed, we found that Eme1 is not upregulated by cells incubated
simultaneously with cetuximab and Stattic (Figure 2D).
Figure 4. Eme1 knockdown eliminates cetuximab-mediated effects on DNA synthesis. (A) A431 cells were transiently transfected with
control siRNA (siC) or Eme1-specific siRNA (siEme1). Forty-eight hours later, the expression levels of Eme1 were quantified by
quantitative real-time PCR as described in Materials and Methods section. The quantification is representative of three independent
experiments. (B) Eme1 expression levels 48 hours following knockdown were assessed by analyzing cell lysates by WB analysis.
Eme1 could only be visualized by additional treatment with 3 μMMG132, which was added 2 hours before lysis; 100 μg/ml cetuximab
was added for 24 hours. (C) A431 cells were transiently transfected for 72 hours with control or Eme1-specific siRNA; 24 hours after
transfection, cetuximab (100 or 500 μg/ml) was added. DNA synthesis was measured by incorporation of BrdU (addition of BrdU
during the last 30 minutes). The data represent mean values and SDs of three experiments. (D) A431 were treated with 100 μg/ml
cetuximab for 1, 24, and 48 hours. Whole-cell lysates were analyzed for the expression and phosphorylation of the designated
proteins by immunoblot analysis.
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(Figure 2E). Whereas untreated cells showed a weak staining,
prominent nuclear staining of Eme1 immunoreactivity was
observed in response to cetuximab (Figure 2E and quantification
in Figure 2F). This suggested that cetuximab led to enhanced levels
of Eme1 in A431 cells, which might be associated with enhanced
DNA synthesis and repair.
Cetuximab Promotes Eme1 Stability
To further evaluate how cetuximab treatment stimulated Eme1
protein expression, we addressed whether cetuximab affected the
transcription or the stability of the protein. Therefore, we investigated
mRNA levels of Eme1 in cetuximab-treated and untreated cells. We
did not observe a significant alteration of Eme1 mRNA expression in
response to cetuximab (Figure 3A).
However, blocking protein degradation with the proteasomal
inhibitor MG132 (Sigma-Aldrich, St. Louis, MO, USA) enhanced
Eme1 protein expression, suggesting that the levels of this protein
might be regulated by the ubiquitin-proteasomal system (Figure 3B
and quantification in Figure 3C). To confirm this hypothesis, we
transfected cetuximab-treated A431 cells with a model substrate of
the proteasome (d1EGFP) (Figure 3D). d1EGFP is a destabilized
enhanced green fluorescence protein, which contains a proline,glutamate, serine, and threonine sequence at its C terminus and has a
half-life of ~1 hour [28,29]. We compared the effect of cetuximab on
Eme1 and d1EGFP. The latter was not stabilized by cetuximab,
arguing that it did not result in a generalized inhibition of ubiquitin-
proteasome–dependent protein degradation (Figure 3D). We
concluded that cetuximab interfered with the stability of Eme1 by
altering its availability to proteasomal degradation (Figure 3, B–D).
Eme1 Mediates Induction of DNA Synthesis
The induction of DNA synthesis and Eme1 expression suggested
that cetuximab treatment promotes an Eme1-dependent increase in
DNA repair. Hence, we investigated whether Eme1 is responsible for
the increased DNA synthesis during incubation with cetuximab
(Figure 4). We suppressed Eme1 in A431 cells using Eme1-specific
siRNAs (siEme1). At the mRNA level, a reduction of 75% was
achieved 48 hours after transfection (Figure 4A). At the protein level,
a reduction of 80% was obtained (Figure 4B). Subsequently, we
investigated the influence of cetuximab on DNA synthesis in Eme1-
expressing and Eme1 knockdown cells. BrdU incorporation
demonstrated that the Eme1 knockdown blocked the increase in
DNA synthesis induced by cetuximab, whereas the transfection of a
control siRNA (siC) was unable to inhibit the cetuximab-dependent
increase in BrdU incorporation (Figure 4C). Furthermore, we
Figure 5. Eme1 mediates cetuximab-induced DNA repair. (A and B), DNA repair was determined by comet assay. (A) Untreated or
cetuximab (100 μg/ml for 24 hours)-treated A431 cells were exposed to UVC light (135 J/cm2). Comet assays were carried out
immediately after irradiation (UVC) or after the cells had recovered for 2 hours at 37°C (UVC (2h)). For each experiment, comet tail lengths
of 30 cells were determined. The data represent mean values and SDs of three experiments. (B) A431 cells were transiently transfected
with control siRNA (siCon) or Eme1-specific siRNA to knockdown Eme1 (siEme1). Forty-eight hours later, 100 μg/ml cetuximab was
added. Comet assays were carried out following 2-hour incubation at 37°C. The analysis was performed as described above. Mean values
and SDs of three experiments. (C) A431 cells were treated with the indicated amounts of cetuximab for 24 hours. Following irradiation
with UVC light (270 J/cm2), cells were incubated in the absence or presence of cetuximab for another 48 hours. Metabolic activity was
measured using an alamarBlue assay. The quantification is representative of three independent experiments. (D) As in C except that the
cells were irradiated with 20 Gy instead of UVC treatment and following irradiation, cells were incubated for 6 days. The quantification is
representative of three independent experiments.
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cells using indirect IF (Figure W3). After cetuximab treatment, we
found as expected a prominent Eme1 staining especially in cell nuclei
incorporating BrdU. Moreover, we detected an increased nuclear
colocalization of BrdU and Eme1. These findings suggest that Eme1
is important for the cetuximab-mediated increase in DNA synthesis.
Cetuximab Triggers DNA Repair through Eme1
To expand on the observations described above, we addressed
whether cetuximab was able to regulate DNA repair. The DNA
damage response (DDR) can be initiated through various signaling
pathways resulting in the activation of distinct DNA repair processes.
Especially the function of the Chk1 was important to us, because it
has been demonstrated that Chk1 influences the activity of the
Mus81/Eme1 endonuclease [30]. Moreover, STAT3 promotes the
DDR and seems to be important for Chk1 activity [31]. Consistent
with this, we observed that in cetuximab-treated cells, the
phosphorylation of Chk1 at serine 296 was elevated (Figure 4D
and quantification in Figure W4). Subsequently, we analyzed the
phosphorylation of additional proteins involved in the DDR. We
found that already the treatment with cetuximab for 1 hourstimulated the phosphorylation of the Chk2 at threonine 68, a
modification that is associated with activity, and Histone H2A.X
serine 139 phosphorylation. The phosphorylation of p53 at serine 15
was elevated after 24 and 48 hours. However, cetuximab did not alter
the phosphorylation of the BRCA1 (Figure 4D and quantification in
Figure W4). Together, these observations are consistent with
stimulation of DNA repair.
To visualize the cetuximab-mediated DNA repair, we next induced
DNA damage in A431 cells using UVC light. UVC exposure creates
UV-specific base alterations such as cyclobutane pyrimidine dimers
and (6-4) photoproducts leading to DNA double-strand breaks
(DSBs) during replication [32,33]. On DNA damage, short DNA
fragments accumulate in the nucleus, which can be visualized by the
comet assay (Figure W5). This assay was performed on cetuximab-
treated and untreated cells immediately after UVC exposure and on
cells that were incubated for two additional hours at 37°C (Figures 5A
and W5). We observed that UVC light induced DNA damage to the
same extent in untreated and in cetuximab-treated cells. However, the
comet tail of cetuximab-treated cells was significantly shorter when
cells were incubated for two additional hours. This indicated that,
within these 2 hours, DNA repair took place, reducing the number of
Figure 6. Eme1 is responsible for survival of UVC-treated cells. A431 cells were transiently transfected with control siRNA or Eme1-
specific siRNA. Following incubation for 24 hours, 100 or 500 μg/ml cetuximab was added. Thereafter, cells were irradiated with UVC light
(135 J/cm2) and incubated for another 24 hours at 37°C. Metabolic cell activity was measured as in Figure 5C. The data of three
experiments were quantified, and mean values and SDs are shown.
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cells, no obvious DNA repair occurred (Figures 5A and W5).
Next, we investigated whether cetuximab-induced DNA repair was
dependent on Eme1. Therefore, we knocked down Eme1 in A431
cells and analyzed the DNA fragmentation in response to UVC
treatment. Eme1 knockdown cells failed to induce DNA repair on
cetuximab treatment (Figure 5B). From this, we concluded that
Eme1 was critically involved in cetuximab-mediated DNA repair.
Cetuximab Induces Cell Survival after Irradiation
The combination of radiotherapywith cetuximab in colorectal cancer
treatment results in reduced response rates. Radiation induces cell death
by DNA damage [34]. As we were able to demonstrate that cetuximab
stimulated DNA repair at least in part by increasing the levels of the
endonuclease Eme1, we investigated whether these cells were more
resistant to DNA damage–induced cell death. Therefore, we treated
A431 cells with UVC light in the presence or absence of cetuximab and
measured metabolic cell activity 24 hours later. Indeed, cetuximab
protected the UVC light–treated cells from death (Figure 5C). The
effect of cetuximabwas dose dependent; the largest effect on cell survival
was achieved with the highest concentration of cetuximab. Hence, we
concluded that after UVC light–induced DNA damage, cetuximab
protected these cells from cell death due to Eme1-mediatedDNA repair.
To address whether this effect was specific for UVC treatment, we
investigated the consequences of megavoltage irradiation on cetuximab-
treated cells (Figure 5D). Cetuximab treatment of the irradiated A431
cells also led to significantly increased cell survival (Figure 5D), even
though the cell death was less dramatic under the experimental
conditions used compared to UV treatment.
Eme1 Is Responsible for DNA Repair and Survival of
Cetuximab-Treated Cells
We then analyzed whether the knockdown of Eme1 sensitized
A431 cells to UVC light. In line with the above-described results, we
observed that metabolic cell activity was decreased significantly in
UVC-treated cells, in which Eme1 was knocked down compared tocontrol cells (Figure 6). Still, a slight increase in survival of UVC-
treated Eme1 knockdown cells was measurable in response to
cetuximab, which might be due to residual Eme1 expression and/or
to a small number of untransfected cells. Taken together, these
findings support the notion that UVC-exposed cetuximab-treated
cells escape death through Eme1-dependent DNA repair.
Cetuximab Triggers Eme1-Mediated DNA Repair in Other
Tumor Cell Lines
A431 cells are protected from UVC-induced DNA damage by
cetuximab-dependent up-regulation of Eme1. To expand our
observations to other tumor cells, we analyzed the effect of cetuximab
on cell lines derived from tumor entities, which are targets of
cetuximab therapy [35,36]. In the breast cancer cell line MDA-MB-
231 and the glioblastoma cell line A172, increased Eme1 protein
levels and BrdU incorporation were measurable on cetuximab
treatment (Figures 7, A–C, and W6). Cetuximab also promoted
survival of these cells after treatment with DNA-damaging agents,
including UVC light and megavoltage irradiation (Figure 7, D–G).
The effect of cetuximab was dose dependent; more cells survived with
higher concentrations of cetuximab, similar to the findings obtained
for A431 cells.
Cetuximab-Mediated Increase of Eme1 Protein in Primary
Glioblastoma Cells
Next, we investigated the effects of cetuximab on Eme1 in cultures
of primary glioblastomas from a cohort of 10 tumor patients
(Figure 8). In 5 of 10 cases, cetuximab caused elevated levels of Eme1
(Figure 8A). We detected a prominent EGFR expression in four of
these five cases. In cetuximab-treated cultures of cells from four
glioblastomas in which Eme1 was increased, we found increased
STAT3 phosphorylation. These findings support our hypothesis that
STAT3 activation results in elevated Eme1 expression in response to
cetuximab application.
The intracellular localization of Eme1 was visualized in one of the
primary tumor cells (GBM1). Untreated cells showed predominantly
Figure 7. Cetuximab triggers DNA repair in breast cancer and glioblastoma cell lines. (A) MDA-MB-231 (breast cancer) and A172 (GBM)
cells were incubated with 100 μg/ml cetuximab for the indicated periods of time. Cell lysates were analyzed for Eme1 and α-Tubulin by
immunoblot analysis. (B and C) MDA-MB-231 (B) or A172 (C) cells were treated with the indicated amounts of cetuximab for 48 hours.
DNA synthesis was determined by measuring incorporation of BrdU. BrdU was added during the last 30 minutes before cell harvesting.
The mean values and SDs of three experiments are illustrated. (D–G) MDA-MB-231 (D and E) or A172 (F and G) cells were treated with
cetuximab for 24 hours as indicated. Following irradiation with UVC light (MDA-MB-231 cells with 135 J/cm2 and A172 cells with 270 J/cm2)
or megavoltage irradiation (MDA-MB-231 cells with 10 Gy and A172 cells with 20 Gy), cells were incubated in the presence or absence of
cetuximab for another 48 hours (UVC) or 6 days (megavoltage irradiation). Metabolic cell activity was measured using the alamarBlue assay.
The quantification is representative of three independent experiments.
216 DNA Repair in Cetuximab Resistance Weinandy et al. Neoplasia Vol. 16, No. 3, 2014cytoplasmic and only weak nuclear Eme1 staining. In response to
cetuximab, the overall staining was enhanced, and in particular,
stronger nuclear Eme1-specific signals were measured (Figure 8B).Additionally, DNA damage was induced in GBM1 cells by UVC
irradiation. As expected, an increased viability of the cetuximab-
treated cells was detected 24 hours after irradiation (Figure 8C). This
Figure 8. Cetuximab treatment leads to elevated levels of Eme1 in primary brain cultures. (A) Primary glioblastoma cells from 10 patients
were treated with 100 μg/ml cetuximab for 24 hours. Whole-cell lysates were analyzed for the indicated proteins by immunoblot analysis.
Cetuximab treatment increased Eme1 protein levels in five primary glioblastomas. (B) Primary glioblastoma cells of one patient (GBM1)
were incubated with 100 μg/ml cetuximab for 24 hours. Eme1 (red) was detected by indirect IF; Hoechst nuclear counterstain (blue).
(C) Cells from patient GBM1 were incubated without or with 100 μg/ml cetuximab for 24 hours. Following irradiation with UVC light (J/cm2),
cells were incubated in the absence or presence of cetuximab for another 48 hours. Metabolic activity was measured using an alamarBlue
assay. The quantification is representative of three independent experiments.
Neoplasia Vol. 16, No. 3, 2014 DNA Repair in Cetuximab Resistance Weinandy et al. 217indicated that at least a subpopulation of primary glioblastoma cells
responded to cetuximab by enhanced Eme1 protein levels and
increased survival after irradiation.
Discussion
The EGFR is highly activated in many tumors [37]. The monoclonal
antibody cetuximab is designed to inhibit EGFR-ligand interaction
and the subsequent activation of downstream factors, which control
cell survival and proliferation [3]. As a consequence of this molecular
targeted therapy, tumor cells should cease proliferation and undergoapoptosis, as shown in a variety of tumor cell lines [38]. However, the
therapeutic efficacy of cetuximab in tumor therapy is only moderate
[4]. Some patients fail to show any response to cetuximab, whereas
others develop resistance later on during cetuximab treatment [6,8].
In the present study, we found that treatment of A431 cells with
cetuximab decreased EGFR phosphorylation and activation of the
signaling kinases Akt and Erk1/2 (Figure 1).However, we did not detect
changes in survival or cell proliferation of nondetached cells, probably
because cetuximab led to elevated activation of STAT3 in these cells
(Figure 1). Lu et al. have shown previously that treatment of A431 cells
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important transcription factor involved in the promotion of cell survival
and proliferation [21]. We found that the inhibition of STAT3 was
sufficient to cause death of A431 cells (Figure W2), confirming reports
on effects of STAT3 inhibition in other tumor cell systems [40]. It is
unclear at present why cetuximab treatment of these cells leads to an
increase in the phosphorylation of STAT3. Diverse mechanisms might
contribute to the increase of activated STAT3 during EGFR inhibition.
For example, Wu et al. demonstrated that the tyrosine kinase inhibitor
gefitinib promotes STAT3 activation by downregulating STAT3
inhibitors such as suppressor of cytokine signaling 1 (SOCS1) and
SOCS3 [41]. Another potential mechanism is mediated through the
elevated nuclear EGFR levels in cetuximab-treated cells in vitro [42].
Lo et al. demonstrated that nuclear EGFR interacts physically and
functionally with STAT3 [43]. It is thus possible that elevated nuclear
EGFR binds to STAT3 leading to STAT3 activation. In this scenario,
the inhibition of EGFR and its downstream signaling pathways by
cetuximab would be reconciled with the simultaneous activation
of STAT3.Moreover, the cross talk between Akt, Erk1/2 and STAT3 is
altered by cetuximab; for example, the inhibition of Akt and Erk1/2may
lead to increased activation of factors controlling STAT3 signaling. It has
been reported that increased STAT3 activation is associated with
acquired resistance to cetuximab therapy [44].
Furthermore, our investigations demonstrate that cetuximab-
mediated activation of STAT3 promotes elevated levels of the
regulatory subunit Eme1 of the heterodimeric endonuclease Mus81/
Eme1 in several tumor cell lines as well as in primary glioblastoma
cells (Figures 2, 7, and 8). Eme1 together with its binding partner
Mus81 forms a structure-specific 3’-flap DNA endonuclease and
cleaves blocked or stalled replication forks [14]. The Mus81/Eme1
complex is involved in DNA repair pathways that remove UV light–
induced DNA lesions and cross-links between DNA strands [45].
Recently, several reports indicated that a deficiency in DNA repair
can play a role in acquired cetuximab resistance. For example, poly-
ADP-ribose polymerase inhibitors have been investigated in tumors,
which are defective in homologous recombination (HR)–mediated
DNA DSB repair [13]. Nowsheen et al. found that additional
treatment of different cancer cell lines with the poly-ADP-ribose
polymerase inhibitor ABT-888 in combination with cetuximab
enhanced cytotoxicity [13]. However, our findings demonstrate that
cetuximab leads to a stabilization of the DNA repair-specific
endonuclease Eme1, with the consequence of elevated Eme1 protein
levels (Figure 3). We observed that the increased Eme1 levels in
cetuximab-treated cells triggered DNA repair (Figures 1C and 5A).
Only when Eme1 levels were reduced by siRNA treatment (Figure 4),
DNA repair could be prevented in cetuximab-treated cells
(Figure 5B). Furthermore, we investigated whether cetuximab
induces changes in DDR pathways [46]. We found that cetuximab
treatment increased the phosphorylation of the checkpoint kinases
Chk1 and Chk2 and its downstream effectors p53 and Histone
H2A.X (Figure 4D). Previous findings indicated a connection
between the Eme1/Mus81-activity and the DDR system [47]. In
fission yeast, for example, the cellular localization of Mus81/Eme1 is
regulated by Cds1, a functional ortholog of human Chk1 [30].
As demonstrated above, cetuximab-mediated STAT3 activation
regulates Eme1 levels. Wee1, a dual-specificity kinase, might also be
involved in the regulation of Eme1-Mus81 activity. Martin et al.
proposed a novel mechanism by which proteasomal degradation of
Wee1 during S and G2/M phases of the cell cycle activates theEme1-Mus81 complex with subsequent cleavage of various
substrates [42,43]. Indeed, we found that cetuximab treatment leads
to a decrease inWee1 total protein levels andWee1 phosphorylation in
A431 cells (Figure W7). These observations suggest that Wee1 could
be a target of cetuximab and that it is activated upstream of Eme1. In
this scenario, cetuximab might inhibit Wee1 phosphorylation, thereby
resulting in the subsequent activation of the Eme1/Mus81 complex.
Under these conditions degradation of Eme1would not be initiated and
thus Eme1 stabilized.
As already mentioned, we observed that Eme1 triggers DNA repair
in cetuximab-treated cells (Figure 5, A and B). DNA repair plays a
central role in the response of cells treated with DNA-damaging
agents such as UVC light or megavoltage irradiation. Our
investigations demonstrate that cetuximab treatment protected
several cancer cell lines from cell death following irradiation with
UVC light or megavoltage X rays (Figures 5, C and D, and 7, D–G).
Cetuximab prevented cell death by inducing DNA repair through
Eme1 (Figures 5, A and B, and 6). In the clinical setting, cetuximab
is often used in combination with radio- and/or chemotherapy
because the efficacy of a cetuximab mono-therapy is quite low.
However, the results from clinical studies that tested cetuximab in
combination with radiochemotherapy differ widely. Some clinical
trials support the use of cetuximab in combination with irradiation.
Other studies failed to demonstrate any considerable improvement of
progression-free survival of the patients or could only demonstrate a
moderate increase in overall survival of 2 to 3 months [4,5].
The mechanisms underlying the failure of such combination
therapies are widely discussed [48,49]. Ryu et al. proposed that the
localization of EGFR plays a crucial role developing a combined
cetuximab and radiotherapy resistance. However, Huang et al.
reported that the loss of p53 that frequently occurs during tumor
progression reduces cell sensitivity to both EGFR inhibitors and
radiation [48,49]. Tomoda et al. demonstrated a link between
elevated Eme1 expression and cisplatin resistance [50]. Cisplatin leads
to the formation of interstrand cross-links [51]. Such cross-links are
repaired by HR involving Eme1/Mus81 [52]. Short wavelength UV
radiation (UVC) and ionizing radiation induce different kinds of
DNA damage, but with a similar outcome, i.e., the formation of
DSBs [53,54]. DSBs are a very toxic form of DNA lesion because
both DNA strands are damaged and the only way to repair DSBs
error-free is by using the complementary DNA strand as a template.
This HR repair is one of the major repair mechanisms of DSBs
[14,55]. The heterodimeric endonuclease Eme1 together with Mus81
plays an essential role in HR repair. The present findings support the
notion that Eme1 is responsible for the development of radiotherapy
resistance with increased Eme1 protein levels been measurable in
cetuximab-treated cells (Figures 2A and 7A). Moreover, recent
findings reported by Barry et al. suggest that STAT3 is important for
efficient DNA repair because it modulates the DDR pathway [31].
Our results show that cetuximab induces the activation of STAT3
and DDR proteins (Figures 1A and 4D).
In conclusion, previous clinical studies showed contradictory
outcomes when cetuximab is used in combination with radiotherapy
[5,56]. We propose that the therapy may fail when cetuximab leads to
increased Eme1 protein levels. These elevated levels of the Mus81/
Eme1 endonuclease, which appear during short-term treatments with
cetuximab, promote error-free DNA repair of DSBs in the irradiation
paradigm, resulting in increased survival of the tumor cells. We expect
that the identification of Eme1 as a negative predictive marker for
Neoplasia Vol. 16, No. 3, 2014 DNA Repair in Cetuximab Resistance Weinandy et al. 219cetuximab therapy resistance will contribute to the development of new,
molecular targeted therapies, in which cetuximab and radiotherapy
could be combined with drugs that inhibit DNA repair pathways.
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Neoplasia Vol. 16, No. 3, 2014 DNA Repair in Cetuximab Resistance Weinandy et al. 220.e1Supplementary materialsFigure W1. Detachment of cetuximab-treated A431 cells induces ce
cetuximab for 1, 3, 24, or 48 hours. Cells were detached from cell cu
determine cetuximab-mediated cell death. The data represent mean v
determined through comparison of cetuximab-treated with untreated
amounts of cetuximab for 72 hours. Metabolic activity was measured
three independent experiments; #P N .05.
Figure W2. Effect of STAT3 inhibition on A431 cells. Exponentially
proliferating A431 cells were incubated with the indicated
increasing amounts of Stattic for 24 hours. Cell viability was
determined using alamarBlue that measures the reducing capacity
of cells. Displayed are mean values and SDs of three independent
experiments; ***P b .001.ll death. (A) A431 cells were incubated without or with (100 μg/ml)
lture plates and incubated with annexin V and Propidium Iodide to
alues and SDs of three experiments. The amount of living cells was
cells; ***P b .001. (B) A431 cells were treated with the indicated
using an alamarBlue assay. The quantification is representative of
Figure W3. Effect of cetuximab on Eme1 localization in BrdU-positive cells. A431 cells were incubated without or with cetuximab
(100 μg/ml) for 48 hours. BrdU was added 30 minutes before cell fixation. Eme1 (green) and BrdU (red) were detected by indirect IF;
scale bar, 10μm.
FigureW4. Effect of cetuximab on activation of DDR. Densitometric analysis of pChk1, pChk2, p-p53, pBRCA1, and pHistone H2A.X from
three experiments was carried out.
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Figure W5. Influence of cetuximab on DNA repair visualized by comet assay. A431 cells were treated with 100 μg/ml cetuximab for 24
hours (C, D, G, and H), irradiated with UVC light (135 J/cm2), and incubated for additional 2 hours at 37°C (E–H). For control cells, they were
left untreated (A and B). DNA repair was determined using a comet assay.
Figure W6. Eme1 levels in MDA-MB-231 and A172 cells. Densitometric analysis of Eme1 protein levels as shown in Figure 6A. The data
represent mean values and SDs of three experiments. (A) MDA-MB-231 cells; (B) A172 cells.
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Figure W7. Effect of cetuximab on Wee1. (A) A431 cells were treated as shown in Figure 1D. The cell lysates were analyzed for the
indicated proteins by immunoblot analysis. (B and C) Densitometric analysis of phosporylated Wee1 (B) or total Wee1 (C); the data
represent mean values and SDs of three experiments.
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